STING agonists have been pursued as immuno-oncologytherapeuticoptions, as they have the potential to activate the innate immuneresponse within the tumor microenvironment and overcome the resistanceagainst immune checkpoint inhibitors. This evidence concerns the gene STING1 and neoplasm.